No. Patients | RF/anti-CCP–positive Patients, 3 Months | RF/anti-CCP–negative Patients, 3 Months | p | RF/anti-CCP–positive Patients, 12 Months | RF/anti-CCP–negative Patients, 12 Months | p | ||||
---|---|---|---|---|---|---|---|---|---|---|
277 | %* | 128 | %* | 277 | %* | 128 | %* | |||
DAS28 remission, % | 64.7 | 75 | 56.5 | 72 | 0.18 | 70.5 | 81 | 69 | 78 | 0.78 |
DAS28(3 variables) remission, % | 66.4 | 86 | 62 | 84 | 0.43 | 72.3 | 91 | 75 | 84 | 0.60 |
Boolean remission, % | 28.6 | 81 | 21.8 | 79 | 0.22 | 32.3 | 85 | 17.3 | 81 | 0.004 |
Boolean(3 variables) remission, % | 32.1 | 75 | 24.5 | 73 | 0.18 | 35.1 | 81 | 21.6 | 80 | 0.014 |
No. Patients | Patients with Erosive Disease at Baseline, 3 Months | Patients with Nonerosive Disease at Baseline, 3 Months | p | Patients with Erosive Disease at Baseline, 12 Months | Patients with Nonerosive Disease at Baseline, 12 Months | p | ||||
---|---|---|---|---|---|---|---|---|---|---|
113 | %* | 291 | %* | 113 | %* | 291 | %* | |||
DAS28 remission, % | 56.2 | 79 | 65.1 | 72 | 0.33 | 63.5 | 75 | 72.7 | 82 | 0.024 |
DAS28(3) remission, % | 59.6 | 88 | 67.5 | 85 | 0.33 | 71.3 | 89 | 74.1 | 89 | 0.071 |
Boolean remission, % | 29.6 | 87 | 25.2 | 78 | 0.53 | 33.7 | 81 | 25.6 | 85 | 0.21 |
Boolean(3) remission, % | 33.3 | 80 | 28.3 | 73 | 0.55 | 37.2 | 76 | 28.8 | 82 | 0.22 |
↵* Percentages refer to the percentage of patients with data available. RF: rheumatoid factor; anti-CCP: anticyclic citrullinated peptide antibodies; DAS28: 28-joint Disease Activity Score.